Safety of Radiolabeled Antibody Therapeutics: Unintended Radiation Exposure to Non-Target Organs

Abstract

Radiolabeled antibody therapeutics, including radioimmunoconjugates and antibody-based radioligand treatments, deliver ionizing radiation selectively to malignant or otherwise diseased cells through antigen-directed binding. Their clinical value depends on achieving a favorable therapeutic index in which tumor absorbed dose is maximized while exposure to normal organs is minimized. Nevertheless, target expression in healthy tissues, circulating immune complexes, vascular permeability, catabolism, renal excretion, and prolonged residence in blood can result in unintended irradiation of the bone marrow, kidneys, liver, lungs, heart, gastrointestinal tract, and other organs. The clinical consequences range from transient cytopenias and biochemical organ injury to delayed myelodysplasia, renal impairment, pulmonary toxicity, or hepatic dysfunction in susceptible patients. Risk is influenced by radionuclide characteristics, antibody pharmacokinetics, administered activity, tumor burden, antigen distribution, prior therapies, organ reserve, and patient-specific clearance. Safe use therefore requires patient selection, baseline organ assessment, dosimetry when feasible, activity modification, radiation-protection procedures, laboratory surveillance, and coordinated multidisciplinary management. Recent advances in antibody engineering, pretargeting, fractionated administration, image-based dosimetry, and alpha-emitting payloads may improve tumor selectivity, although these technologies introduce distinct safety considerations. This review summarizes the mechanisms, clinical manifestations, diagnostic approach, treatment strategies, and guideline-based principles relevant to unintended radiation exposure from radiolabeled antibody therapeutics.

Introduction

Radiolabeled antibodies combine the molecular specificity of monoclonal antibodies with the cytotoxic potential of radioactive emissions. After binding to an antigen on tumor cells, the therapeutic radionuclide emits beta particles, alpha particles, or, in some applications, Auger electrons that damage DNA directly or through the generation of reactive molecular species. The approach is particularly attractive for hematologic malignancies and selected solid tumors in which the target antigen is sufficiently abundant and accessible. However, molecular specificity is not equivalent to exclusive tumor localization. Antigens may be expressed at lower levels in normal tissues, while antibody distribution is also affected by blood-pool exposure, endothelial permeability, Fc-receptor interactions, reticuloendothelial uptake, and renal or hepatobiliary elimination.

Unintended radiation exposure is therefore a predictable pharmacologic issue rather than an exceptional event. Its clinical importance depends on the relationship between absorbed dose and tissue tolerance. The same administered activity may be acceptable for one patient but hazardous for another because of differences in renal function, marrow reserve, body composition, prior chemotherapy, or disease-related organ involvement. A safety-focused evaluation must integrate molecular biology, radiation physics, pharmacokinetics, clinical medicine, and regulatory requirements.

Epidemiology / Disease Burden

The burden of toxicity varies according to the therapeutic platform, radionuclide, disease indication, treatment schedule, and duration of follow-up. In clinical practice, hematologic toxicity is among the most consistently observed adverse effects because circulating antibodies expose marrow and because many target-positive blood malignancies are closely associated with marrow compartments. Thrombocytopenia, neutropenia, and anemia may be acute or delayed, with nadirs commonly occurring weeks after administration. Prolonged cytopenias can increase infection risk, bleeding risk, transfusion requirements, and treatment interruptions.

Renal exposure is especially relevant for smaller antibody fragments and radiolabeled agents undergoing glomerular filtration or proximal tubular reabsorption. Hepatic and splenic uptake is common for intact immunoglobulins and may be amplified by Fc-mediated clearance, high tumor burden, or altered reticuloendothelial function. In solid tumors, heterogeneous antigen expression and abnormal vascular permeability may produce high intratumoral variability, while normal organs with physiological antigen expression can receive clinically meaningful dose. Long-term complications, including therapy-related myeloid neoplasms, are uncommon but important because they may emerge months or years after treatment and can be confounded by previous cytotoxic exposure.

Pathophysiology

Normal-organ irradiation results from several complementary mechanisms. First, on-target, off-tumor binding occurs when the intended antigen is expressed by healthy cells. Even low-density expression may become clinically relevant if the antibody has high affinity, prolonged circulation time, or repeated dosing. Second, non-specific distribution contributes to exposure in the blood, liver, spleen, and vascular endothelium. Third, catabolism of the antibody can generate radiolabeled metabolites that redistribute to organs involved in elimination.

Radiation injury is determined by absorbed dose, dose rate, radiation quality, tissue radiosensitivity, and the volume of exposed tissue. Beta emissions have a relatively longer path length and can irradiate neighboring cells, producing a cross-fire effect that is beneficial in tumors with heterogeneous antigen expression but may increase injury near normal tissues. Alpha particles have high linear energy transfer and a short path length, permitting potent cell killing over a very limited range. This may improve tumor-cell lethality but makes microdistribution and accidental uptake particularly important. Bone marrow injury reflects direct irradiation of hematopoietic cells and stem-cell compartments, whereas renal injury may involve tubular retention, endothelial damage, and progressive loss of functional nephrons. Delayed malignancy risk is associated with radiation-induced genomic instability and cumulative exposure, especially when combined with previous alkylating agents, topoisomerase inhibitors, or external-beam radiation.

Risk Factors

Important patient-related risk factors include reduced glomerular filtration, hepatic dysfunction, pre-existing cytopenias, extensive marrow involvement, poor nutritional status, advanced age, and prior intensive chemotherapy or radiotherapy. A history of myelodysplastic syndrome, leukemia, chronic kidney disease, or clinically significant liver disease should prompt careful reassessment of treatment suitability. High tumor burden may increase antibody sequestration and alter clearance, whereas low target expression can reduce tumor uptake and increase the relative proportion of circulating drug available to normal tissues.

Therapy-related factors include high administered activity, repeated cycles without adequate recovery, prolonged antibody half-life, unstable radiolabeling, and radionuclides with inappropriate physical characteristics for the target geometry. Concomitant nephrotoxic or hepatotoxic medicines may magnify organ injury. Inadequate hydration, failure to follow amino-acid or renal-protection protocols where indicated, and insufficient radiation-safety planning can increase avoidable exposure. Immunogenicity and anti-drug antibodies may alter pharmacokinetics unpredictably, while impaired clearance may occur in patients with abnormal Fc-receptor function or substantial circulating antigen.

Clinical Features

Clinical manifestations depend on the organ receiving the highest absorbed dose and the timing of injury. Marrow toxicity commonly presents with fatigue, recurrent infection, fever, bruising, mucosal bleeding, or symptomatic anemia. Renal injury may initially be asymptomatic and detected through rising serum creatinine, declining estimated glomerular filtration rate, proteinuria, or changes in tubular markers. Hepatic exposure can produce transaminase elevation, cholestatic abnormalities, hepatomegaly, or, rarely, clinically significant hepatic dysfunction.

Pulmonary exposure may cause cough, dyspnea, hypoxemia, or interstitial inflammatory changes, although respiratory toxicity is generally dependent on the specific agent and pre-existing lung disease. Gastrointestinal irradiation may result in nausea, vomiting, diarrhea, abdominal discomfort, or mucosal injury. Delayed complications can include persistent marrow suppression, therapy-related myeloid neoplasia, chronic renal impairment, and organ-specific fibrosis. Symptoms should not automatically be attributed to radiation, because infection, disease progression, immune-mediated effects, medication toxicity, and metabolic abnormalities may produce similar presentations.

Diagnosis

Assessment begins with a detailed treatment history, including the antibody construct, radionuclide, administered activity, prior cycles, cumulative exposure, concomitant therapies, and known target expression. Baseline evaluation generally includes complete blood count with differential, renal and hepatic biochemical testing, assessment of performance status, and review of prior marrow-toxic treatment. Additional tests should be guided by the agent and clinical context.

Serial laboratory monitoring is essential because cytopenias and renal injury may be delayed. When available, quantitative imaging and patient-specific dosimetry can estimate absorbed doses to tumors and critical organs. Planar imaging, single-photon emission computed tomography, or positron emission tomography may be used depending on the radionuclide and tracer properties. Dosimetry should be interpreted alongside uncertainty in organ segmentation, biological clearance, and dose-rate effects. Bone marrow assessment may be indicated for prolonged unexplained cytopenias or suspicion of a secondary myeloid neoplasm. Renal imaging, urinalysis, pulmonary function testing, or cross-sectional imaging may be appropriate when organ-specific toxicity is suspected.

Treatment & Management

Management is primarily preventive and supportive. Before treatment, clinicians should confirm the indication, target suitability, organ function, pregnancy status where relevant, and the absence of uncontrolled infection or severe marrow compromise. Administered activity should follow the approved product information and institutional protocol, with individual adjustment when validated dosimetric or organ-function criteria support modification. Hydration, renal-protection measures, antiemetic therapy, and prescribed amino-acid solutions should be used according to the specific radionuclide and route of clearance.

After administration, blood counts and renal and hepatic tests should be monitored at intervals appropriate to the expected toxicity nadir. Growth-factor support, transfusion, antimicrobial therapy, and treatment delay or discontinuation may be required for clinically significant marrow suppression. Suspected renal injury warrants removal of nephrotoxic exposures, optimization of volume status, dose reassessment, and nephrology consultation when deterioration is substantial or persistent. Severe hepatic, pulmonary, or gastrointestinal toxicity requires organ-specific evaluation and exclusion of alternative causes. There is no universal pharmacologic antidote for radiation absorbed after antibody binding; therefore, early recognition and prevention are more effective than rescue treatment.

Radiation-protection practice must include controlled handling, contamination prevention, appropriate shielding, occupational monitoring, patient instructions, and communication with household contacts. Institutional radiation-safety officers and nuclear medicine specialists should define discharge criteria and precautions based on the radionuclide, administered activity, patient living circumstances, and local regulations. Multidisciplinary coordination among medical oncology, nuclear medicine, radiation safety, pharmacy, dosimetry, nephrology, and hematology improves consistency and reduces preventable exposure.

Recent Advances / Emerging Therapies

Antibody engineering is increasingly focused on improving tumor-to-normal-tissue ratios. Smaller fragments may penetrate solid tumors more rapidly and clear from blood sooner, although renal retention can become more prominent. Albumin-binding modifications, altered Fc interactions, site-specific conjugation, and optimized affinity aim to control circulation time and reduce non-specific uptake. Pretargeting separates antibody delivery from radionuclide administration, allowing the antibody to localize first and a rapidly clearing radioactive component to bind subsequently. This strategy may reduce blood-pool and normal-organ exposure, but its safety depends on efficient in vivo chemistry and reliable timing.

Personalized dosimetry using serial quantitative imaging and pharmacokinetic modeling may permit activity selection based on organ tolerance rather than fixed population-based dosing. Fractionated regimens can allow normal tissues to recover while maintaining cumulative tumor exposure. Alpha-emitting agents offer potent short-range cytotoxicity and may be valuable for micrometastatic or resistant disease, but their biological effects make accurate target localization, manufacturing quality, and long-term surveillance particularly important. Emerging theranostic systems that pair diagnostic imaging with therapeutic radionuclides may improve treatment selection and provide an individualized estimate of target expression and clearance.

Guideline Recommendations

Current clinical and regulatory principles support treatment only in appropriately equipped centers with trained personnel, validated handling procedures, and access to dosimetry and emergency support. Clinicians should document baseline hematologic, renal, and hepatic status; evaluate prior cumulative radiation and chemotherapy exposure; confirm target expression when required; and review reproductive precautions. Product-specific prescribing information should determine activity limits, contraindications, laboratory thresholds, hydration requirements, and follow-up schedules.

Patient-specific dosimetry is recommended or strongly encouraged when supported by the agent, available technology, and clinical evidence, particularly for repeat treatment, borderline organ function, unusual pharmacokinetics, or investigational protocols. Dose should be withheld, reduced, or discontinued when predefined marrow or organ toxicity criteria are met. Long-term follow-up should address persistent cytopenias, renal function, secondary malignancy risk, and late organ effects. Evidence remains heterogeneous across agents, so recommendations should be interpreted within national regulations, specialty-society guidance, institutional protocols, and the characteristics of the individual radiolabeled antibody.

Conclusion

Unintended radiation exposure to non-target organs is an intrinsic and clinically manageable risk of radiolabeled antibody therapeutics. Toxicity reflects the interaction of antigen distribution, antibody pharmacokinetics, radionuclide physics, administered activity, patient organ reserve, and previous treatment. Bone marrow, kidneys, liver, and other normal tissues require systematic evaluation before, during, and after therapy. Patient selection, organ-protective measures, quantitative imaging, individualized dosimetry, laboratory surveillance, and multidisciplinary radiation-safety practice are central to maintaining therapeutic benefit. Advances in antibody design, pretargeting, fractionation, and theranostic planning are likely to improve the therapeutic index, but they must be accompanied by rigorous validation and long-term safety monitoring. A mechanism-based and guideline-concordant approach allows clinicians to exploit targeted radiation while reducing avoidable injury to healthy organs.